Arizona is putting $5 million in state money behind a clinical trial of ibogaine, a psychoactive compound that remains federally illegal and carries a documented risk of fatal heart rhythm disturbance.
Barrow Neurological Institute received the grant from the Arizona Department of Health Services to conduct a Phase 1/2 trial in people with neurological conditions including traumatic brain injury, the institute announced. The study is double-blind and placebo-controlled, aims to enroll 40 participants with chronic TBI symptoms, and will split them evenly between ibogaine and placebo. Researchers hope to enroll the first participant in 2027.
